Shots:
- 3SBio & its subsidiaries will grant Pfizer exclusive license to develop, manufacture & market SSGJ-707 worldwide, excl. China, with an option to obtain marketing rights in China
- As per the deal, 3SBio will receive $1.25B upfront & ~$4.8B in development, regulatory & commercial milestones, plus double-digit tiered royalties on SSGJ-707 sales; closing is expected in Q3’25 followed by a $100M equity investment from Pfizer subject to a securities subscription agreement
- SSGJ-707 (anti-PD-1 & anti-VEGF BsAb) to enter a 3SBio-led P-III trial in China in 2025, with Pfizer planning to manufacture the drug substance in Sanford, North Carolina, & the drug product in McPherson, Kansas
Ref: Pfizer | Image: Pfizer & 3SBio | Press Release
Related News:- Pfizer to Discontinue Danuglipron’s Development Program for Chronic Weight Management
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
